Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06264843 · ClinicalTrials.gov registry record

Peripheral Bypass Trial for Completion Control

A clinical trial of Chronic Limb-Threatening Ischemia, sponsored by Medistim A.

Recruiting
Registry status
450
Enrollment target
1
Study location

NCT06264843 is a study of Chronic Limb-Threatening Ischemia that is actively recruiting participants, run by Medistim A. The registered enrollment target is 450 participants, above the 135-participant average among 9 other Chronic Limb-Threatening Ischemia trials with a reported enrollment target (233% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06264843, a study of Chronic Limb-Threatening Ischemia, is actively recruiting participants, sponsored by Medistim A.

RECRUITING
Registry status
450 participants
Enrollment target
1
Study location

Study Summary

The goal of the study is to identify and validate flow measurement and ultrasound images in patients undergoing vein bypass surgery below-knee and above ankle

Interventions

  • DEVICE MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes

Study Locations (1)

California

  • University of California - San Francisco

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2024-11-14
Est. Completion 2027-12

Sponsor

Medistim A

1 total trials

What the Registry Record Tells You About NCT06264843

The ClinicalTrials.gov registry entry for NCT06264843 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 9 other Chronic Limb-Threatening Ischemia trials with a reported enrollment target (233% higher). The listed sponsor is Medistim A, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Limb-Threatening Ischemia appearing as the primary indexed condition, and to 1 intervention - of which MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes is the first listed.

NCT06264843 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06264843 about?

NCT06264843 is a clinical study titled "Peripheral Bypass Trial for Completion Control". The goal of the study is to identify and validate flow measurement and ultrasound images in patients undergoing vein bypass surgery below-knee and above ankle

What is the current status of trial NCT06264843?

This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2024-11-14. Estimated completion is 2027-12.

What conditions does trial NCT06264843 study?

This clinical trial studies the following conditions: Chronic Limb-Threatening Ischemia.

What interventions are being tested in trial NCT06264843?

The interventions under investigation include: MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes (DEVICE).

Who is sponsoring clinical trial NCT06264843?

This trial is sponsored by Medistim A, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06264843 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Limb-Threatening Ischemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.